Results 221 to 230 of about 7,672 (251)

Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings. [PDF]

Drugs Context
Hasan I, Murti IS, Bayupurnama P, Kalista KF, Hill-Zabala C, Kananda D, Viayna E.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion:  A randomized trial

Indian Journal of Gastroenterology, 2023
Terlipressin and noradrenaline are effective in the management of hepatorenal syndrome (HRS). There are no reports on the combination of these vasoconstrictors in type-1 HRS.To evaluate terlipressin with or without noradrenaline in type-1 HRS not responding to terlipressin at 48 hours.Sixty patients were randomized to receive either terlipressin (group
Virendra Singh, Akshaya Jayachandran, Arka De, Akash Singh, Shivani Chandel, Navneet Sharma   +5 more
openaire   +2 more sources

Terlipressin in Hepatorenal Syndrome

Annals of Pharmacotherapy, 2011
Objective: To compare the pharmacology, dosing, and adverse reactions of vasopressin and terlipressin for the treatment of hepatorenal syndrome (HRS) and assess the efficacy of the investigational drug terlipressin for HRS. Data Sources: Articles evaluating prospective studies for vasopressin and terlipressin were discussed after being identified ...
Joseph F. Dasta, Tanna B. Cooper, Joseph E Mazur   +2 more
openaire   +2 more sources

Terlipressin in the management of liver disease

Expert Opinion on Pharmacotherapy, 2023
Terlipressin is a synthetic vasopressin analog which has been recently approved in the United States by the Food and Drug Administration for the treatment of hepatorenal syndrome. Terlipressin stimulates vasopressin receptors located on the smooth muscle vasculature of the splanchnic circulation and renal tubules which results in splanchnic ...
Andrew R Scheinberg, Paul Martin, Joshua A Turkeltaub   +2 more
openaire   +2 more sources

Terlipressin in brain‐death donors

Clinical Transplantation, 2012
AbstractBackgroundMetabolic management of brain‐death organ donors includes correction of the hormonal perturbations that occur after cerebral death and impair circulatory function. Vasopressin is a hormone secreted by the posterior pituitary gland, which contributes to maintain systemic blood pressure by regulating urine secretion and small arteriole ...
Michele Iannuzzi, Giuliana Scarpati, Ornella Piazza, Ornella Piazza, Rosalba Tufano, Edoardo De Robertis, Fabio Rispoli   +6 more
openaire   +6 more sources

Terlipressin for hepatorenal syndrome

2012
Clinical trials suggest that terlipressin improves renal function in hepatorenal syndrome, but the evidence concerning mortality is equivocal.To assess the beneficial and harmful effects of terlipressin alone or with albumin versus placebo, no intervention or albumin for hepatorenal syndrome.Eligible trials were identified through electronic (The ...
Gluud, Lise Lotte, Christensen, Kurt, Christensen, Erik, Krag, Aleksander   +3 more
openaire   +3 more sources

Terlipressin for hepatorenal syndrome

2006
Terlipressin may reverse some of the circulatory changes associated with hepatorenal syndrome.To assess the beneficial and harmful effects of terlipressin for hepatorenal syndrome.Electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Register, the Cochrane Central Register of Controlled Trials in ...
L L, Gluud, M S, Kjaer, E, Christensen
openaire   +2 more sources